Exela Pharma Company Profile
What is the competitive landscape for EXELA PHARMA
EXELA PHARMA has twenty-three approved drugs.
There are seventeen US patents protecting EXELA PHARMA drugs.
Drugs and US Patents for Exela Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,648,262 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 018925-001 | Mar 30, 1984 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,510,941 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma Science | CAFFEINE CITRATE | caffeine citrate | SOLUTION;INTRAVENOUS | 077233-001 | Sep 21, 2006 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 10,905,714 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,969,439 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-003 | Apr 9, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

